(Q37976993)

26 August 2017

title

(Q)SAR modeling and safety assessment in regulatory review (English)

1 reference

26 August 2017

N L Kruhlak

1

1 reference

26 August 2017

R D Benz

series ordinal

2

1 reference

26 August 2017

H Zhou

series ordinal

3

1 reference

26 August 2017

T J Colatsky

series ordinal

4

1 reference

26 August 2017

language of work or name

English

0 references

publication date

18 January 2012

1 reference

Clinical Pharmacology & Therapeutics

26 August 2017

published in

1 reference

26 August 2017

volume

91

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

529-534

1 reference

Recent advances in fragment-based QSAR and multi-dimensional QSAR methods

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

Genetic toxicology in the 21st century: reflections and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

Describing the validity of carcinogen screening tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

Computational toxicology in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

The influence of drug-like concepts on decision-making in medicinal chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

Toxicological and clinical computational analysis and the US FDA/CDER.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES software

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: I. Identification of carcinogens using surrogate endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR software.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

In Silico Screening of Chemicals for Genetic Toxicity Using MDL-QSAR, Nonparametric Discriminant Analysis, E-State, Connectivity, and Molecular Property Descriptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

A comprehensive model for reproductive and developmental toxicity hazard identification: I. Development of a weight of evidence QSAR database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

A comprehensive model for reproductive and developmental toxicity hazard identification: II. Construction of QSAR models to predict activities of untested chemicals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

Prediction of drug-related cardiac adverse effects in humans--A: creation of a database of effects and identification of factors affecting their occurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

Prediction of drug-related cardiac adverse effects in humans--B: use of QSAR programs for early detection of drug-induced cardiac toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

In silico approaches to explore toxicity end points: issues and concerns for estimating human health effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

Combined Use of MC4PC, MDL-QSAR, BioEpisteme, Leadscope PDM, and Derek for Windows Software to Achieve High-Performance, High-Confidence, Mode of Action-Based Predictions of Chemical Carcinogenesis in Rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

The current status and future applicability of quantitative structure-activity relationships (QSARs) in predicting toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

7 January 2021

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

7 January 2021

Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans. Part A: use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

7 January 2021

Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part C: use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

7 January 2021

Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.300

7 January 2021

Identifiers

DOI

10.1038/CLPT.2011.300

1 reference

Dimensions Publication ID

26 August 2017

1010325259

0 references

1 reference